DFTX — Definium Therapeutics, Inc.
—
Nasdaq ·
Materials ·
Chemicals ·
CIK 1813814 ·
Last close
$43.52
Market Cap
$5.78B
52W High
$49.20
52W Low
$19.33
ADV30
3,773,317
Next earnings
2026-08-06
Quarterly Fundamentals
Revenues vs Net Income (last 4 Q)
Assets vs Liabilities (last 4 Q)
| Period | Revenues | GrossProfit | OpIncome | NetIncome | Assets | Cash | Liabilities |
|---|---|---|---|---|---|---|---|
| Mar 2026 | 0 | — | -59,220,000 | -77,098,000 | 401,293,000 | 262,518,000 | 122,444,000 |
| Dec 2025 | 0 | — | -47,578,000 | -50,436,000 | 440,100,000 | 257,837,000 | 107,773,000 |
| Sep 2025 | 0 | — | -45,669,000 | -67,265,000 | 236,916,000 | 19,959,000 | 106,320,000 |
| Jun 2025 | 0 | — | -40,903,000 | -42,744,000 | 265,091,000 | 33,392,000 | 79,691,000 |
Cashflow TTM (yfinance, fills SEC gap)
Operating CF
$-131,560,000
Investing CF
$-151,606,000
Financing CF
$267,269,000
CapEx
—
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$-2.04
As of
2026-05-10
Balance + Analyst (yfinance extras)
Retained Earnings
$-582,672,000
Inventory
—
Receivables
—
ST Investments
$153,756,000
EBIT TTM
$-178,311,000
Pretax Income TTM
$-183,793,000
Interest Exp TTM
$5,482,000
Analysts
15
Annual Trend (SEC EDGAR, last 4y)
Revenues vs Net Income (last 4y)
| FY end | Revenues | OpIncome | NetIncome | Assets | Liabilities | Equity | OCF |
|---|---|---|---|---|---|---|---|
| Dec 2025 | 0 | -166,309,000 | -183,793,000 | 440,100,000 | 107,773,000 | — | -131,560,000 |
| Dec 2024 | 0 | -103,916,000 | -108,679,000 | 302,151,000 | 60,703,000 | — | -79,129,000 |
| Dec 2023 | 0 | -93,866,000 | -95,732,000 | 124,541,000 | 46,407,000 | — | -64,365,000 |
| Dec 2022 | 0 | -66,331,000 | -56,796,000 | 169,993,000 | 19,076,000 | — | -50,139,000 |
TTM Snapshot
Revenues TTM
—
NetIncome TTM
—
OpCashFlow TTM
—
Assets (Latest)
—
Forward EPS
$-1.51
Max Pain — expiry 2026-08-21
max pain strike: $40.00 · spot: $43.52 · call oi: 17,904 · put oi: 8,666
Expected Move to 2026-08-21:
±$10.20
(23.44%) —
implied range
$33.32 –
$53.72
· ATM straddle on $44.00 strike
Peers — same industry
| Ticker | Name | Market Cap | Last | Daily % |
|---|---|---|---|---|
| BCPC | BALCHEM CORP | $5.38B | $167.56 | — |
| SXT | SENSIENT TECHNOLOGIES CORP | $5.26B | $123.67 | — |
| CSW | CSW INDUSTRIALS, INC. | $5.20B | $318.93 | — |
| ICL | ICL Group Ltd. | $6.53B | $5.06 | — |
| PRM | Perimeter Solutions, Inc. | $4.99B | $30.61 | — |
News headlines (Yahoo Finance, 1h cache)
Wall Street Analysts See a 34.86% Upside in Definium Therapeutics, Inc. (DFTX): Can the Stock Really Move This High?
2026-07-31 13:55 · Yahoo
Definium Therapeutics to Report Second Quarter 2026 Financial Results on August 6, 2026
2026-07-30 20:01 · Yahoo
Definium Therapeutics (DFTX) Redefines Depression & Anxiety Treatment
2026-07-30 13:21 · Yahoo
CMPS, MDGL, DFTX, GHRS, HELP Stocks In Spotlight Today – Why Wells Fargo Thinks Next Wave Of Depression Drugs Could Create New Winners
2026-07-27 14:38 · Yahoo
Psychedelic Therapy Meets M&A: Fireside Chat with Jupiter Neurosciences CEO Christer Rosén & President Alison Silva
2026-07-22 17:25 · Yahoo
Definium Therapeutics (DFTX) Highlights GAD Care Gaps, Is The Stock Already Overvalued?
2026-07-22 14:14 · Yahoo
How New GAD Treatment Gap Data At Definium Therapeutics (DFTX) Has Changed Its Investment Story
2026-07-22 07:10 · Yahoo
Psychedelic drugs are going mainstream
2026-07-21 04:00 · Yahoo
Definium Therapeutics Announces New Employee Inducement Grants
2026-07-20 20:01 · Yahoo
Definium Therapeutics Launches Wired for Worry, a Health Care Provider Initiative to Advance the Understanding of Generalized Anxiety Disorder (GAD) Patient Impact and Neurobiology
2026-07-16 11:00 · Yahoo
Recent Insider Activity
No insider activity indexed for this ticker.